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doi:10.1016/j.jfma.2011.08.004Background/Purpose: Hospital readmission rates are usually higher for stroke than for other
chronic conditions. To prevent readmission, effective clinical services and accurate estimates
of the absolute readmission rates are required. This study examined the patterns of care
received by patients with ischemic stroke, estimated stroke readmission rates, and identified
predictors related to readmission in Taiwan.
Methods: A retrospective analysis of the claims database of the Bureau of National Health
Insurance in 2004e2007 was performed. This study included ischemic stroke patients who
survived hospitalization and whose initial admission occurred in 2006. Time-dependent Cox
regression models were developed separately to identify predictors of readmission within 1
month, 6 months, and 1 year after index discharge.
Results: We identified 1194 patients from the data set. At the initial stroke, the care provided
was almost fully concordant with evidence-based practice guidelines, and the prevalence of
antiplatelet therapy was 87.8%. The percentage of patients regularly taking antiplatelet agents
within 1 month, 6 months, and 1 year after the index discharge was 65.0%, 18.8%, and 8.0%,
respectively. The stroke readmission rates for survivors at 1 month, 6 months, and 1 year after
the index discharge were 9.9%, 23.0%, and 30.7%, respectively. Older age, diabetes, longer
length of stay for the index admission, and continuous use of antiplatelet agents less than
9 months after the index discharge were all predictors of readmission for acute ischemic stroke.
Conclusion: Stroke readmissions are not related to receipt of less than optimum or below stan-
dard health care during index admission in Taiwan. Additional stroke readmissions in Taiwan
might be avoided if more patients used antiplatelet agents for a longer period.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.ang, Institute of Health Policy and Management, National Taiwan University, 6/F, 17, Suchow Road,
du.tw (M.-C. Yang).
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628 H.-W. Li et al.Stroke, the second leading cause of death, is also a leading
cause of disability among the elderly in Taiwan.1 Clinically,
approximately 70% of acute stroke events result in hospi-
talization.2 Stroke patients not only have longer lengths of
stay, but also higher readmission rates and medical
expenditures compared with patients with other chronic
conditions.2,3
Readmission of elderly disabled stroke patients,
a common occurrence in clinical practice, increases the
costs of health care and causes emotional distress in
patients.4 From a quality of care standpoint, hospital read-
missions may reflect unresolved problems at discharge.3
Furthermore, recent studies have suggested that hospital
readmissions can be used to make international comparisons
of quality and efficiency.5 Therefore, to reduce the number
of unnecessary readmission events, manage the cost of acute
care, and improve quality of care, the factors that influence
the readmission rate among stroke patients must first be
identified.
While some factors related to hospital readmission
among stroke patients have been identified, the search for
factors has only focused on demographic characteristics,
physical function, discharge planning and long term care.
Few studies have examined factors related to clinical
diagnosis and treatment services. Moreover, the reason for
hospital readmission after stroke varies (e.g. stroke recur-
rence, acute myocardial infarction, and respiratory
illness6), but the hospital readmission diagnosis in many of
the previous studies was not limited to recurrent stroke,
but included all types of disease.3,6e8
Previous studies in developed countries have estimated
readmission rates for stroke ranging from 23.0% to 43.8%
within 6 months and 32.5% to 58.8% within 1 year after
discharge,3,4 but these estimates vary significantly between
countries with different socioeconomic conditions and
populations with different ethnic backgrounds. Such vari-
ability emphasizes the need to identify factors that influ-
ence stroke recurrence, so as to design population-specific
preventive strategies.9 Moreover, few studies have esti-
mated the readmission rates for stroke in Taiwan.10 Since
the management stroke differs according to type, the focus
of the present study was ischemic strokes, which are more
common than hemorrhage strokes. We examined the rates
of hospital readmission of ischemic stroke survivors,
patterns of care during initial ischemic stroke and after
discharge, and the relationship between practice patterns
(following evidence-based practice guidelines) and hospital
readmission of ischemic stroke survivors in Taiwan.
Methods
Subjects
This study used the longitudinal health insurance database
containing one million individuals randomly sampled from
the claims database of the Bureau of National Health
Insurance (BNHI) during the period of 2004e2007. Patients
with an International Classification of Disease, Ninth Edition
(ICD-9-CM) diagnosis code of 433 or 434 were included in
the sample if their index hospitalization (initial admission)
occurred in 2006.A total of 2257 patients were identified with ischemic
stroke as the primary or secondary diagnosis. To ensure that
the initial admission occurred in 2006, this study excluded
900 patients who were diagnosed with stroke in 2004 or
2005. To collect 1 year of follow-up data after discharge,
we excluded 15 patients not discharged in 2006. Further-
more, to ensure that the patients in this study were still
alive, 148 patients without readmission records within
1 year of discharge and without medical records more than
1 year after discharge were also excluded. Therefore, the
sample consisted of 1194 eligible patients.
Variables
The main outcome variables were the occurrence of stroke
readmission within 1 month, 6 months, and 1 year after the
index stroke discharge. The independent variables were the
patient characteristics, factors related to index admission,
and prescription patterns after index discharge. The
patient characteristics included age, sex, and comorbid-
ities. The comorbidities included the presence (before the
initial admission) of hypertension, diabetes, ischemic heart
disease, heart failure, atrial fibrillation, and transient
ischemic attack, and were identified by ICD-9-CM codes.
The factors related to index admission included length of
stay (LOS), causes of ischemic stroke, and examination and
prescription procedures. The causes of ischemic stroke
included stenosis (ICD-9-CM Z 433), thrombosis (ICD-9-
CM Z 434.0), embolism (ICD-9-CM Z 434.1), and unspeci-
fied cerebral artery occlusion (ICD-9-CM Z 434.9). Exami-
nation and prescription procedures were defined based on
evidence-based practice guidelines regarding ischemic
stroke.11e16 Examination procedures included brain scans
(computed tomography or magnetic resonance imaging),
electrocardiograms, chest X-rays, and complete blood
counts. Prescription procedures included the use of throm-
bolytic agents, anticoagulants, and antiplatelet agents.
As mentioned in the evidence-based practice guidelines,
thrombolytic agents and antiplatelet agents are recom-
mended for acute ischemic stroke, but the emergency use
of an anticoagulant is associated with a modest but signifi-
cantly increased risk of hemorrhagic transformation of the
ischemic stroke or serious non-neurological bleeding.11e17
Antiplatelet therapy should be continued in the long term
for the secondary prevention of recurrent stroke. Warfarin
should be considered for use in stroke with non-valvular
atrial fibrillation, but the use of subcutaneous unfractio-
nated heparin is not recommended for preventing early
stroke recurrence.11e16 We found that 73.4% of prescriptions
of antiplatelet agents were refill prescriptions. To investi-
gate the effect of continuous medication use, prescription
patterns after index discharge were assessed by recording
the number of months of continuous anticoagulant or anti-
platelet agent use.
Statistical analysis
SPSS version 11.5 software was used for all statistical anal-
yses. Descriptive statistics such as frequency, percentage,
and mean and standard deviation were used to examine
the characteristics of patients, factors relevant to index
Table 2 Distribution of factors related to index admission
Variables n (%)
Mean LOS  SD (d) 11.9  18.8
Causes of ischemic stroke
Stenosis 146 (12.2)
Thrombosis 26 (2.2)
Embolism 30 (2.5)
Unspecified occlusion 992 (83.1)
Diagnostic procedures
Brain scanning (CT or MRI) 1126 (94.3)
ECG 1137 (95.2)
Chest X-ray 1161 (97.2)
CBC 1189 (99.6)
Prescriptions
Antiplatelet agents 1048 (87.8)
Anticoagulants agents 202 (16.9)
Thrombolytic agents 15 (1.3)
CT Z computed tomography; MRI Z magnetic resonance
imaging; LOS Z length; SD Z standard deviation;
ECG Z electrocardiogram; CBC Z complete blood count.
Table 3 Prescription patterns after index discharge
Duration of continuous
medication use after
Antiplatelet
agents n (%)
Anticoagulant
agents n (%)
Predictors for readmission of acute ischemic stroke 629admission, patterns of prescription after discharge and
readmission rates within 1 month, 6 months, and 1 year
after the index stroke discharge. A test of the proportional
hazards assumption for each categorical variable found that
continuous use of antiplatelet agents was a time-dependent
covariate. Time-dependent Cox regression models were
separately established to identify predictors of readmission
within 1 month, 6 months, and 1 year after the index
discharge.
Results
Characteristics of patients
The demographic characteristics of the patients (59.3%
men; mean age [all patients], 68.0  12.8 years) are pre-
sented in Table 1. Approximately 80.2% of ischemic stroke
patients had a history of hypertension; therefore, hyper-
tension was the most common comorbidity, followed by
diabetes and ischemic heart disease.
Factors related to index admission
The results shown in Table 2 indicate that the mean LOS at
initial stroke admission was 11.9  18.8 days. The strokes
were caused by stenosis in 146 (12.2%) patients, thrombosis
in 26 (2.2%) patients, embolism in 30 (2.5%) patients, and
unspecified cerebral artery occlusion in 992 (83.1%)
patients. Patients were assessed by brain scan (n Z 1126;
94.3%), electrocardiogram (n Z 1137; 95.2%), and chest
X-ray (n Z 1161; 97.2%). Almost everyone was given
a complete blood count. Treatments for the initial ischemic
stroke were antiplatelet agents (n Z 1048; 87.8%), anti-
coagulants (n Z 202; 16.9%), and thrombolytic agents
(n Z 15; 1.3%).
Patterns of prescription after index admission
discharge
Table 3 shows the prescription patterns among ischemic
stroke patients after index admission discharge. The
percentage calculations were based on the number of
patients who continued to receive prescriptions after indexTable 1 Characteristics of 1194 ischemic stroke inpa-
tients in 2006
Variables n (%)
Sex (male/female) 708 (59.3)/486 (40.7)
Mean age  SD (yr) 68.0  12.8
Comorbidity
Hypertension 958 (80.2)
Diabetes mellitus 510 (42.7)
Ischemic heart disease 412 (34.5)
Heart failure 137 (11.5)
Atrial fibrillation 121 (10.1)
Transient ischemic attack 75 (6.3)
SD Z standard deviation.discharge. The findings revealed that among 776 (65.0%)
patients receiving antiplatelet agents within 1 month, only
224 (18.8%) continued to receive antiplatelet agents for 6
months and only 96 (8.0%) continued to receive antiplatelet
agents for 1 year. Moreover, 65 (5.4%) patients were receiving
anticoagulant agents within 1 month after discharge, and
most of these prescriptions were short-term.
Readmission rates and predictors of readmission
The results of the three time-dependent Cox regression
models are summarized separately in Tables 4e6. From the
2 log likelihood values, these three models were all well
suited for identifying factors affecting the risk of stroke
readmission within 1 month, 6 months, and 1 year. Theindex discharge
1 mo 776 (65.0) 65 (5.4)
2 mo 572 (47.9) 52 (4.4)
3 mo 431 (36.1) 36 (3.0)
4 mo 339 (28.4) 27 (2.3)
5 mo 270 (22.6) 20 (1.7)
6 mo 224 (18.8) 16 (1.3)
7 mo 181 (15.2) 15 (1.3)
8 mo 155 (13.0) 13 (1.1)
9 mo 126 (10.6) 12 (1.0)
10 mo 114 (9.5) 11 (0.9)
11 mo 103 (8.6) 10 (0.8)
12 mo 96 (8.0) 9 (0.8)
Medications never used
after index discharge
309 (25.9) 1102 (92.3)
Medication use, sporadic 109 (9.1) 27 (2.3)
Table 4 Factors related to stroke readmission within 1 month after index discharge (time-dependent Cox regression)
Factors B p Exp (B)
Age 0.007 0.357 1.007
Sex (male/female) 0.059 0.766 0.943
Comorbidity
Hypertension (no/yes) 0.037 0.882 1.037
Diabetes mellitus (no/yes) 0.368 0.060 1.444
Ischemic heart disease (no/yes) 0.173 0.397 1.189
Transient ischemic attack (no/yes) 0.330 0.360 1.391
Heart failure (no/yes) 0.258 0.342 1.295
Atrial fibrillation (no/yes) 0.278 0.357 1.320
Length of stay of index admission 0.003 0.309 1.003
Causes of ischemic stroke 0.722
Thrombosis versus stenosis 0.778 0.458 0.459
Embolism versus stenosis 0.012 0.985 1.012
Unspecified occlusion versus stenosis 0.193 0.547 1.212
Diagnostic procedures used during index admission
Brain scan (no/yes) 0.178 0.653 0.837
ECG (no/yes) 0.128 0.766 0.880
Chest X-ray (no/yes) 0.445 0.470 1.560
Full blood count (no/yes) 1.111 0.142 0.329
Drugs prescribed during index admission
Antiplatelet agents (no/yes) 0.459 0.097 1.583
Anticoagulants agents (no/yes) 0.090 0.731 0.914
Thrombolytic agents (no/yes) 0.757 0.313 2.132
Drugs prescribed after index admission discharge
Antiplatelet agents within 1 mo (no/yes) 2.886y <0.001 0.056
Anticoagulants agents within 1 mo (no/yes) 1.882* 0.013 0.152
2 Loglikelihood (overall) 1548.443y <0.001
*p < 0.05.
yp < 0.001.
ECG Z electrocardiogram.
630 H.-W. Li et al.stroke readmission rates for survivors at 1 month, 6 months,
and 1 year after index admission discharge were 9.9%,
23.0%, and 30.7%, respectively. The number of months of
continuous antiplatelet agent use was most significantly
related to stroke readmissions within 1 month, 6 months,
and 1 year. Anticoagulant therapy within 1 month after
index discharge reduced the possibility of stroke read-
mission at 1 month, but the effect disappeared at 6 months
and 1 year. In addition, older age, diabetes as a comorbid-
ity, and prolonged LOS for the index admission increased
the risk of stroke readmission within 6 months and 1 year
after index discharge. Furthermore, the presence of
ischemic heart disease was slightly related to stroke read-
mission within 6 months after index discharge.Discussion
This study found that in Taiwan, the readmission rates for
ischemic stroke at 1 month, 6 months, and 1 year after
index discharge were 9.9%, 23.0%, and 30.7%, respectively,
which were not higher than those in developed countries
(23.0e43.8% at 6 months3,4 and 32.5e58.8% at 1 year after
the initial stay3).Different mechanisms of ischemic stroke may lead to
different prognoses and result in different risks of recur-
rence. Our time-dependent Cox regressions, after control-
ling for all the characteristics of patients, found that the
cause of ischemic stroke was not a predictor of stroke
readmission. Using the Kaplan-Meier method, the rates of
readmission for stenosis, thrombosis, and embolism at 1
year after index discharge were 25.34%, 23.08%, and
33.33%, respectively. These rates were not significantly
different by log rank analysis. In addition, our data
revealed that the cause of ischemic stroke in 83.1% of cases
was unspecified, indicating that physicians usually do not
attempt to identify the cause of ischemic stroke to make
a definite diagnosis clinically in Taiwan.
LOS was a significant predictor of readmission within 6
months and 1 year after index discharge, but not within 1
month. A previous study suggested that LOS could be used
as a crude proxy for stroke severity, particularly when
patients who died during index hospitalization or immedi-
ately after discharge were excluded.18 Although the extent
to which LOS can serve as a proxy of stroke severity remains
an open question, we believe that LOS as an indicator of
stroke severity is reasonable and reflects the readmission
rate over the long term.
Table 5 Factors related to stroke readmission within 6 months after index discharge (time-dependent Cox regression)
Factors B p Exp (B)
Age 0.014y 0.007 1.015
Sex (male/female) 0.210 0.105 0.811
Comorbidity
Hypertension (no/yes) 0.0066 0.686 1.068
Diabetes mellitus (no/yes) 0.346y 0.006 1.413
Ischemic heart disease (no/yes) 0.263* 0.048 1.301
Transient ischemic attack (no/yes) 0.211 0.465 0.810
Heart failure (no/yes) 0.015 0.935 0.985
Atrial fibrillation (no/yes) 0.316 0.110 1.371
Length of stay of index admission 0.010z <0.001 1.011
Causes of ischemic stroke 0.317
Thrombosis versus stenosis 0.007 0.990 1.007
Embolism versus stenosis 0.222 0.642 0.801
Unspecified occlusion versus stenosis 0.293 0.155 1.341
Diagnostic procedures used during index admission
Brain scan (no/yes) 0.160 0.555 0.852
ECG (no/yes) 0.131 0.662 0.877
Chest X-ray (no/yes) 0.110 0.754 0.896
Full blood count (no/yes) 0.608 0.421 0.545
Drugs prescribed during index admission
Antiplatelet agents (no/yes) 0.329 0.138 1.389
Anticoagulants agents (no/yes) 0.178 0.319 1.195
Thrombolytic agents (no/yes) 0.127 0.866 1.136
Prescription patterns after index admission discharge
Continuous use of antiplatelet agents for 6 mo after discharge <0.001
Used for 1 mo 0.511* 0.026 0.600
Continuously used for 2 mo 1.834z <0.001 0.160
Continuously used for 3 mo 2.979z <0.001 0.051
Continuously used for 4 mo 4.144z <0.001 0.016
Continuously used for 5 mo 9.860y 0.004 < 0.001
Continuously used for 6 mo 36.434* 0.017 < 0.001
Used, but not continuously 3.852z <0.001 0.021
Use of anticoagulant agents continuously for 6 mo after discharge 0.299
2Loglikelihood (overall) 3434.672z <0.001
*p < 0.05.
yp < 0.01.
zp < 0.001.
ECG Z electrocardiogram.
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at initial stroke in Taiwan are almost concordant with
evidence-based practice guidelines; in particular, the rate
of antiplatelet agent use at the initial stroke was high (i.e.
87.8%). Moreover, patterns of clinical services at index
admission were not significantly associated with the risk of
readmission in the time-dependent Cox regression models,
suggesting that stroke readmissions in Taiwan are not
produced by incomplete health care or premature hospital
discharge at index admission.
Although the efficacy of thrombolytic therapy within 3
hours of ischemic stroke onset has been well established,
this study demonstrated that only 1.3% of patients in
Taiwan received thrombolytic agents at the initial stroke.
This may be because of the complicated contraindications
of thrombolytic therapy; furthermore, physicians cannot be
sure when the patient’s ischemic stroke occurred.Prior investigations have shown that age,7 race,7,19
smoking,9 hypertension,9,20 atrial fibrillation,9,20 diabetes,2
physical function at discharge,3,21 complications related to
damage to the brain and concomitant heart disease22 are
associated with readmission among stroke patients. Of all
the comorbidities of stroke (i.e. hypertension, diabetes,
ischemic heart disease, transient ischemic attack, heart
failure, and atrial fibrillation), only diabetes was identified
by the present study as a risk factor in Taiwan.
This study additionally demonstrated that the number of
months of continuous use of antiplatelet agents after index
admission was a significant predictor of stroke readmission
among ischemic stroke patients. Although this demonstra-
tion is supported by the evidence-based practice guide-
lines,11e16,23 our study found that the percentage of
patients receiving antiplatelet agents was 65.0% at 1 month,
18.8% at 6 months, and only 8.0% at 1 year after discharge.
Table 6 Factors related to stroke readmission within 1 year after index admission discharge (time-dependent Cox regression)
Factors B p Exp (B)
Age 0.020z <0.001 1.020
Sex (male/female) 0.201 0.077 0.818
Comorbidity
Hypertension (no/yes) 0.102 0.479 1.108
Diabetes mellitus (no/yes) 0.380y 0.001 1.462
Ischemic heart disease (no/yes) 0.154 0.188 1.167
Transient ischemic attack (no/yes) 0.244 0.334 0.784
Heart failure (no/yes) 0.008 0.962 0.992
Atrial fibrillation (no/yes) 0.291 0.099 1.338
Length of stay of index admission 0.012z < 0.001 1.012
Causes of ischemic stroke 0.180
Thrombosis versus stenosis 0.143 0.756 1.154
Embolism versus stenosis 0.155 0.685 1.168
Unspecified occlusion versus stenosis 0.390 0.039 1.477
Diagnostic procedures used during index admission
Brain scan (no/yes) 0.267 0.266 0.766
ECG (no/yes) 0.099 0.707 0.905
Chest X-ray (no/yes) 0.153 0.630 0.858
Full blood count (no/yes) 0.317 0.670 0.728
Drugs prescribed during index admission
Antiplatelet agents (no/yes) 0.246 0.203 1.279
Anticoagulants agents (no/yes) 0.148 0.350 1.159
Thrombolytic agents (no/yes) 0.195 0.754 1.215
Prescription patterns after index admission discharge
Used antiplatelet agents continuously for 6 mo after discharge <0.001
Used for 1 mo 0.579y 0.004 0.560
Continuously used for 2 mo 1.351z <0.001 0.259
Continuously used for 3 mo 2.238z <0.001 1.107
Continuously used for 4 mo 2.322z <0.001 0.098
Continuously used for 5 mo 2.965z <0.001 0.052
Continuously used for 6 mo 3.083z <0.001 0.046
Continuously used for 7 mo 3.634y 0.002 0.026
Continuously used for 8 mo 4.029z <0.001 0.018
Continuously used for 9 mo 13.302 0.961 <0.001
Continuously used for 10 mo 47.836 0.299 <0.001
Continuously used for 11 mo 10.968 0.110 <0.001
Continuously used for 12 mo 23.412 0.115 <0.001
Used, but not continuously 3.119z <0.001 0.044
Use of anticoagulant agents continuously for 6 mo after discharge 0.335
2 Log likelihood (overall) 4671.871z <0.001
*p < 0.05.
y
p < 0.01.
zp < 0.001.
ECG Z electrocardiogram.
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missions in Taiwanmight have been avoided if more patients
had continued to receive antiplatelet agents for a longer
period of time. Furthermore, our three time-dependent Cox
regression models also revealed that 9 months of continuous
antiplatelet therapy was required to reduce the readmission
rate within 1 year after discharge. Since only a few patients
received medications continuously for some time periods
(e.g. only 7 patients continuously received antiplatelet
therapy for 11 months but not to 12 months), we combined
the data for 2 months. The 1-year readmission rate was21.82% after continuous treatment with antiplatelet agents
for 7e8 months and 4.35% after treatment for 9e10 months.
In conclusion, we suggest that ischemic stroke patients
should continuously use antiplatelet agents for at least
9 months to reduce the risk of stroke readmission within
1 year of index discharge.
The decrease in the percentage of patients receiving
antiplatelet agents over time might be because patients
were not accustomed to receiving all their health care from
one physician. Although our data showed that 76.0% of
patients visited the same hospital for stroke outpatient
Predictors for readmission of acute ischemic stroke 633services within 1 month after discharge, it might decline
over time. Our study results should alert clinicians to the
need for preventing stroke readmission by prescribing
antiplatelet agents.
When considering the relationship between prescription
procedures by physicians and stroke recurrence, drug
compliance may also be a risk factor. A previous study24
found that medication compliance was lower in stroke
patients (68%) than in myocardial infarction patients (90%).
Similar drug regimens reduce the risk of stroke and
myocardial infarction. The reason for low compliance by
stroke patients was simply not feeling the need for medi-
cation. Therefore, educational interventions should be
targeted to such patients.
This study has some limitations. Since it was based on
the claim database of BNHI, disease classification can be
inaccurate and analytical data may be incomplete. For
example, miscoding cannot be avoided, and out-of-pocket
services are not included. Furthermore, the exact time of
prescription and examination at initial stroke onset was not
available. Additionally, data on other factors influencing
stroke readmission, such as rehabilitation and patient
behaviors, were not available. These limitations may be
overcome in future studies by reviewing clinical records or
by examining the effect of different antiplatelet agent
doses25 or different antiplatelet agent contents26e28 on
stroke recurrence.References
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